-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 29, Buchang Pharmaceuticals announced that its wholly-owned subsidiary Shandong Danhong's parecoxib sodium for injection was approved for listing
.
Parecoxib sodium for injection is a selective COX-2 inhibitor, and its terminal sales in China's public medical institutions will exceed 2 billion yuan in 2020
.
Up to now, Buchang Pharmaceuticals has already reviewed 10 products
.
Parecoxib is a non-steroidal anti-inflammatory drug.
It is the world's first selective cyclooxygenase-2 (COX-2) inhibitor that can be injected intravenously and intramuscularly at the same time.
Compared with inhibitors, it has the characteristics of good analgesic effect, rapid onset, long-lasting effect, and can effectively inhibit pain hypersensitivity
.
According to data from Menet.
com, the domestic market of Parecoxib has continued to expand in recent years.
In 2020, the terminal sales of parecoxib in Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2 billion yuan.
, An increase of 10.
22% year-on-year
.
Sales of Parecoxib in China's public medical institutions (unit: 10,000 yuan) Source: Meinenet.
In addition to the original manufacturer Pfizer, 30 domestic pharmaceutical companies have been approved to produce Parecoxib sodium for injection.
, of which over 24 enterprises assessment, including Qilu pharmaceutical, Cologne medicine, CTTQ, Hengrui medicine, pharmaceutical and other steps
.
Buchang Pharmaceuticals passed/deemed passed consistency evaluation varieties source: Meinnet Consistency Evaluation Database In recent years, Buchang Pharmaceuticals has made frequent efforts in the field of chemical medicine
.
Up to now, Buchang Pharmaceuticals (including subsidiaries) has passed/deemedly passed the consistency evaluation of 10 varieties, including apixaban tablets, rivaroxaban tablets, lacosamide tablets, captopril tablets, Six varieties of parecoxib sodium for injection and levetiracetam concentrated solution for injection have all been reviewed this year
.
Data source: Minet database, company announcement
.
Parecoxib sodium for injection is a selective COX-2 inhibitor, and its terminal sales in China's public medical institutions will exceed 2 billion yuan in 2020
.
Up to now, Buchang Pharmaceuticals has already reviewed 10 products
.
Parecoxib is a non-steroidal anti-inflammatory drug.
It is the world's first selective cyclooxygenase-2 (COX-2) inhibitor that can be injected intravenously and intramuscularly at the same time.
Compared with inhibitors, it has the characteristics of good analgesic effect, rapid onset, long-lasting effect, and can effectively inhibit pain hypersensitivity
.
According to data from Menet.
com, the domestic market of Parecoxib has continued to expand in recent years.
In 2020, the terminal sales of parecoxib in Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will exceed 2 billion yuan.
, An increase of 10.
22% year-on-year
.
Sales of Parecoxib in China's public medical institutions (unit: 10,000 yuan) Source: Meinenet.
In addition to the original manufacturer Pfizer, 30 domestic pharmaceutical companies have been approved to produce Parecoxib sodium for injection.
, of which over 24 enterprises assessment, including Qilu pharmaceutical, Cologne medicine, CTTQ, Hengrui medicine, pharmaceutical and other steps
.
Buchang Pharmaceuticals passed/deemed passed consistency evaluation varieties source: Meinnet Consistency Evaluation Database In recent years, Buchang Pharmaceuticals has made frequent efforts in the field of chemical medicine
.
Up to now, Buchang Pharmaceuticals (including subsidiaries) has passed/deemedly passed the consistency evaluation of 10 varieties, including apixaban tablets, rivaroxaban tablets, lacosamide tablets, captopril tablets, Six varieties of parecoxib sodium for injection and levetiracetam concentrated solution for injection have all been reviewed this year
.
Data source: Minet database, company announcement
